Lytix Biopharma AS - New share capital registered

23 Dec 2024 17:03 CET

Oslo, Norway, 23 December 2024: Reference is made to the stock exchange
announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 17
December 2024 (the "Announcement") regarding the successful completion of a
private placement (the "Private Placement") of new shares raising NOK 100
million in gross proceeds, and a retail offering (the "PrimaryBid Offering") of
new shares raising NOK 11.3 million in gross proceeds via the PrimaryBid
platform (together with the new shares in the Private Placement, the “Offer
Shares”).

The share capital increase relating to the Private Placement and the PrimaryBid
Offering has today been registered with the Norwegian Register of Business
Enterprises (the "NRBE"). In total 18,549,131 Offer Shares have been issued
through the Private Placement and the PrimaryBid Offering. The Company's new
share capital is NOK 6,815,943.40, divided into 68,159,434 shares, each with a
par value of NOK 0.10.

The Offer Shares are expected to be registered in the Norwegian Central
Securities Depository (VPS) today, on 23 December 2024, or on 27 December 2024.

The share capital increase relating to the 102,568 shares to be issued to settle
part of the fee to underwriters in the Private Placement, as further described
in the Announcement, has not yet been registered with the NRBE.

Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company's
continuing obligations as a company listed on Euronext Growth Oslo.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site